Drug reference

inotuzumab ozogamicin

antibody-drug conjugate (ADC), anti-CD22 · anticancer

antibody-drug conjugate (ADC), anti-CD22anticancer

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Inotuzumab ozogamicin is a humanized anti-CD22 antibody-cytotoxic drug conjugate. After binding to CD22-positive tumor cells and cellular uptake, the cytotoxic ozogamicin is released via hydrolytic cleavage. Ozogamicin binds to the minor groove in DNA, induces double-strand breaks, and causes cell death.

Indications

relapsed or refractory ALL

Side effects

Serious

hepatotoxicity (including hepatic veno-occlusive disease)
bone marrow suppression

Related guidelines

Generalised anxiety disorder and panic disorder

NICE · Psychiatry · 2020

Ask House about inotuzumab ozogamicin

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team